Enlivex Therapeutics Investor Relations Material
Latest events
Company Presentation
3 Jun, 2025
Q4 2024
29 Apr, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Enlivex Therapeutics Ltd
Access all reports
Enlivex Therapeutics Ltd is an Israel-based clinical-stage biopharmaceutical company focused on developing allogeneic cell therapies for life-threatening immune-related diseases. The company’s lead investigational product is designed to modulate the immune system to restore immune balance in conditions such as sepsis, solid tumors, and other inflammatory disorders. Enlivex conducts clinical trials and research to advance its immunotherapy platform. The company is headquartered in Nes Ziona, Israel, and its shares are listed on the NASDAQ.
Key slides for Enlivex Therapeutics Ltd
Company Presentation
Enlivex Therapeutics Ltd
Company Presentation
Enlivex Therapeutics Ltd
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
ENLV
Country
🇮🇱 Israel